CSRXP URGES HOUSE LAWMAKERS TO CONTINUE WORKING ACROSS PARTY LINES TO HOLD BIG PHARMA ACCOUNTABLE

10-16-2019 Press Release

Trio of Committee Proceedings on Drug Pricing Offer Chance to Focus on Areas of Bipartisan Consensus Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday ahead of three legislative proceedings on drug pricing proposals scheduled for Thursday. The U.S. House Committee on Ways and Means is slated to hold a […]

CSRxP Urges E&C Lawmakers to Continue Building Bipartisan Consensus

09-23-2019 Press Release

Hearing on Drug Pricing Proposals an Opportunity for Focus on Areas of Agreement to Hold Big Pharma Accountable and Lower Drug Prices  Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday ahead of a U.S. House Committee on Energy and Commerce Subcommittee on Health hearing Wednesday titled “Making Prescription Drugs More […]

CSRxP: House Rx Package Adds to Unprecedented Momentum to Hold Big Pharma Accountable

09-19-2019 Press Release

Speaker’s Drug Pricing Plan Includes Measures That Have Won Support from Both Sides of the Aisle Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today on the release of details of a drug pricing plan circulated by U.S. House Speaker Nancy Pelosi (D-CA). “The plan unveiled by leaders in the […]

CSRxP: HHS OIG REPORT DRASTICALLY UNDERCUTS BIG PHARMA’S BLAME GAME AT CRITICAL MOMENT IN WASHINGTON

09-13-2019 Press Release

Inspector General Finds Negotiated Rebates Slowed Medicare Part D Price Hikes, Saved Program $8 Billion on Drug Costs Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today following the release of a new report from the U.S. Department of Health & Human Services (HHS) Office of Inspector General on rebates […]

NEW STUDY: BIG PHARMA PRICE-GOUGING MEDICATIONS FOR RARE DISEASES AT STAGGERING RATE

09-11-2019 Press Release

Orphan Drug Prices 25 Times More Expensive Than Traditional Drugs, AHIP Finds Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today following the release of a new report from America’s Health Insurance Plans (AHIP) that found Big Pharma manipulated The Orphan Drug Act in order to raise the prices of […]

CSRxP Commends Administration for Commitment to DTC Advertising Rule

08-21-2019 Press Release

Applauds HHS For Appealing Ruling Against List Price Transparency Measure Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today after the U.S. Department of Health and Human services appealed a federal ruling blocking the implementation of a measure to require drug makers to disclose list prices in direct-to-consumer (DTC) advertising. […]

Second Opinion: GAO Undermines Common Refrain in Big Pharma’s Blame Game

08-16-2019 Press Release

Analysis Finds PBMs Pass On Over 99 Percent of Rebates, Used to Keep Premiums Down A new report from the Government Accountability Office (GAO) undermines a common refrain in Big Pharma’s blame game targeting pharmacy benefit managers (PBMs) and rebates. In an effort to distract from their own price-gouging and anti-competitive behavior, Big Pharma frequently […]

CSRxP: Senate Finance Takes Positive Steps to Hold Big Pharma Accountable, Lower Drug Prices

07-25-2019 Press Release

Commends Bipartisan Collaboration on Several Market-Based Solutions, Cautions Committee Leaders Against Revival of Misguided Rebate Rule Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Thursday commending members of the U.S. Senate Committee on Finance for advancing a drug pricing package that contains a number of measures that will hold Big […]

CSRxP Applauds Grassley, Wyden for Moving Ahead on Drug Pricing Package

07-23-2019 Press Release

Looks Forward to Working With Senate Finance Members to Hold Big Pharma Accountable  Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Tuesday commending Chairman Chuck Grassley (R-IA) and Ranking Member Ron Wyden (D-OR) for moving ahead with a U.S. Senate Committee on Finance package to lower prescription drug prices. On […]

Big Pharma Earnings Watch: Novartis

07-18-2019 Press Release

Drug Makers’ Shares Hit ‘All-Time High’ Off Of Price-Gouging American Patients Today Big Pharma giant Novartis announced better-than-expected earnings for the second quarter of 2019. The brand name drug maker reported $11.76 billion in sales in Q2 – up from $11.34 billion last year – beating analysts’ expectations. As a result, the company raised its […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.